A new idea is often the start of scientific discovery. But it is transformational new technology that often enables researchers to act upon these ideas and to explore previously unreachable frontiers. PLEX® Elite 9000, Swept-Source OCT from ZEISS*, is such a technology that is bringing together researchers, clinicians and scientists from around the world to help bring meaningful innovation in eye care, today and into the future.
With ZEISS PLEX Elite Swept-Source OCT Angiography, clinical researchers now have the potential to see deeper, wider and in more detail from the vitreous to the sclera in the posterior segment.
- Montage scan acquisition workflow and export features showcase the ability to rapidly acquire an ultra-wide OCT angiography En face montage for unprecedented visualization of retinal vasculature with a field of view up to 70º
- Ultra-wide 15x9 high-density scan reveals the widest field of view captured in a single OCT angiography scan
- NEW! Glaucoma applications including OCTA for glaucoma and other optic neuropathies
Ultra-wide 15x9 AngioPlex map of choroidal neovascular membrane, RPE/RPE Fit layer;
Image courtesy of Dr. Philip Rosenfeld, Bascom Palmer Eye Institute, Miami, FL.
Ultra-widefield AngioPlex montage of proliferative diabetic retinopathy, superficial layer; Image courtesy of Dr. Jean-François Korobelnik, University Hospital Pellegrin, Bordeaux, France.
Ultra-wide angiography En face montage; Image courtesy of Dr. Giuseppe Querques, San Raffaele Ospedale, Milan, Italy.
Building on the groundbreaking successes of the A R I Network, the A N G I Network with PLEX Elite® 9000 Swept-Source OCT from ZEISS brings together leading clinicians from around the world and ZEISS scientists to pave the way for meaningful innovation in glaucoma and optic nerve disease management.
Joel S. Schuman
A N G I Network Chairman
New York, NY
To advance our understanding of glaucoma pathogenesis, as well as that of optic neuropathies in general, and to further our abilities to detect glaucoma and other optic neuropathies and identify their progression, the A N G I Network collaboratively investigates retinal and optic nerve vasculature with the PLEX Elite swept source OCT. Bringing together investigators globally, A N G I is the surest way to advance the field, to enhance diagnosis and the assessment of the efficacy of our treatments.Joel S. Schuman, MD, FACS; Director, NYU Langone Eye Center; Chairman, A N G I Network Steering Commitee
Amsterdam, The Netherlands
Jeffrey L. Goldberg
Palo Alto, CA, USA
Kyung Rim Sung
Seoul, South Korea
Christopher Kai Shun Leung
Hong Kong, HK
Drag each slider side-to-side to track disease progression in this DR patient over just four months. Slide to the right to see the DR patient's first visit image. Slide to the left to see the second image, four months later.
Images courtesy of Dr. Jean-François Korobelnik, University Hospital Pellegrin, Bordeaux, France.
This is a case of young diabetic patient with severe proliferative diabetic retinopathy in both eyes. The new montage scan acquisition feature on the PLEX Elite 9000 is able to capture ultra-wide OCT angiography images that in this case helped the clinician clearly visualize the significant increase in the proliferation of new vessels in both eyes.
Complete the form to the right to receive immediate access to the case study download file.
- Advance the science of retina by collaborating with leading peers from around the world.
- Access the latest innovations in retinal imaging technology.
- Exchange ideas and connect with technology specialists at ZEISS to accelerate development and improve the standard of care.
Research and technology is only as good as how rapidly it is adopted throughout the world. What you see from this collaborative effort is that it is being adopted throughout the world, on every continent.Philip Rosenfeld, MD, PhD
Philip Rosenfeld, MD, PhD (A R I Network Steering Committee Chair) — USA
Philip Rosenfeld, MD, PhD
Bascom Palmer Eye Institute, University of Miami
Research Interest: Age-Related Macular Degeneration
"By easily identifying non-exudative, subclinical neovascularization in eyes with presumed 'dry' AMD, the PLEX Elite 9000 has changed my definition of 'dry' AMD, changed my understanding of disease progression, and changed the way I follow these patients. In designing clinical trials to test therapies for all stages of 'dry' AMD, we now need to identify these subclinical lesions and stratify for them at baseline to be sure they are well-balanced between treatment arms since the onset of exudation is such an important study endpoint."
Robyn Guymer, MBBS, PhD — Australia
Robyn Guymer, MBBS, PhD, FRANZCO, FAAHMS
Centre for Eye Research, University of Melbourne
Research Interest: Age-related macular degeneration
"It is exciting to be able to identify choroidal neovascular complexes in cases of age-related macular degeneration where there was little evidence, based upon our current understanding, that they would be present."
Frank G. Holz, MD, F.E.B.O. — Germany
Frank G. Holz, MD
Research Interests: Retinal imaging; phenotyping, anatomical and functional clinical endpoint development and validation, pathophysiology and treatments for macular and retinal diseases, pathogenesis and therapy of complex and monogenetic macular diseases including age-related macular degeneration (AMD), macular telangiectasia 2, and retinal vascular diseases
"With the A R I Network, I gain access to applications in various research projects of the most advanced high-resolution imaging modalities, in addition to being part of an international collaboration with outstanding experts in the field."
Peter Kaiser, MD — USA
Peter Kaiser, MD
The Cleveland Clinic
Research Interests: Age-related macular degeneration
"The amazing aspect of being part of the A R I network is the collaboration with other pioneers throughout the world to develop the best swept-source OCT system. I especially enjoy the close collaboration with the engineers to develop better algorithms to evaluate our patient scans."
Jean-François Korobelnik, MD — France
Jean-François Korobelnik, MD
Hôpital Pellegrin, University of Bordeaux
Research Interests: AMD, Diabetic retinopathy, epidemiology, retinal surgery, vitrectomy, drug development
"Widefield OCT-A and automatic mosaic is definitely the most exciting part. Being able to evaluate the perfusion of the periphery of the retina in a few minutes, without injecting a dye, without moving the patient from one instrument to another, is easy, useful and impressive"
Toshinori Murata, MD, PhD — Japan
Toshinori Murata, MD, PhD
Shinshu University, School of Medicine
Research Interest: OCT-angiography guided laser treatment
"What excites me the most is being part of an engagement in a global collaborative research on retinal imaging with internationally renowned specialists and exchanging ideas on differing approaches and the prospect of developing a new modality of therapy."
Key Considerations in the Purchase of Advanced Ophthalmic Diagnostics: The Evolution of OCT Technology
White Paper by Shareef Mahdavi
The A R I Network with PLEX ELITE 9000 Swept-Source OCT from ZEISS
System offers advanced capabilities in OCT, OCTA
Modern Retina from Ophthalmology Times
ZEISS PLEX Elite 9000 Swept-Source OCT allows clinical researchers the potential to see deeper, wider and in more detail from the vitreous to the sclera in the posterior segment. Want to see for yourself? Tell us more about you, and a ZEISS representative will be in touch to schedule a visit.
* ZEISS PLEX ELITE 9000 is CE Marked and is available for sale in selected countries and in the United States.
Not all products, services or offers are approved or offered in every market and approved labeling and instructions may vary from one country to another. For country specific product information, see the appropriate country website. Product specifications are subject to change in design and scope of delivery as a result of ongoing technical development.